---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-22-000020"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2022-07-20T23:59:59+00:00"
generated_at: "2026-06-24T11:52:49.150709+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biogen Q2 revenue $2.59B, GAAP EPS $7.24; raises full-year guidance

## Summary
- Q2 total revenue $2,589M, down 7% YoY; MS revenue $1,719M (-4%), SPINRAZA $431M (-14%).
- GAAP diluted EPS $7.24; Non-GAAP diluted EPS $5.25.
- FDA granted Priority Review for lecanemab (Alzheimer's) with decision by Jan 6, 2023; Phase 3 data expected Fall 2022.
- Second positive Phase 3 for zuranolone in PPD; joint U.S. filing for MDD and PPD expected H2 2022.
- Launched BYOOVIZ (biosimilar Lucentis) in U.S.; raised full year 2022 financial guidance.

## SEC filing metadata
- accession: 0000875045-22-000020
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2022-07-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504522000020/0000875045-22-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504522000020/biib-20220720.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-22-000020
- JSON: https://secwatch.observer/filing/0000875045-22-000020.json
- Plain text: https://secwatch.observer/filing/0000875045-22-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.